Century Therapeutics, Inc. Operating Lease Cost
Century Therapeutics, Inc. (IPSC) reported Operating Lease Cost of $1.59 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-12
- Century Therapeutics, Inc. operating lease, cost for the quarter ending 2026-06-30 was $1.59M, a 8.64% decline year-over-year.
- Century Therapeutics, Inc. operating lease, cost for the quarter ending 2026-03-31 was $1.63M, a 6.65% decline year-over-year.
- Century Therapeutics, Inc. operating lease, cost for the quarter ending 2025-12-31 was $664.00K, a 62.14% decline year-over-year.
- Century Therapeutics, Inc. operating lease, cost for the quarter ending 2025-09-30 was $2.60M, a 57.80% increase year-over-year.
- Century Therapeutics, Inc. operating lease, cost for fiscal 2025 was $6.74M, a 0.71% decline from fiscal 2024.
- Century Therapeutics, Inc. operating lease, cost for fiscal 2024 was $6.79M, a 18.00% increase from fiscal 2023.
- Century Therapeutics, Inc. operating lease, cost for fiscal 2023 was $5.75M, a 19.82% increase from fiscal 2022.
- Century Therapeutics, Inc. operating lease, cost for fiscal 2022 was $4.80M, a 112.90% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.59M 10-Q · filed 2026-08-12 | $3.21M 10-Q · filed 2026-08-12 | $3.88M derived: sum of 3 quarters · filed 2026-08-12 | $6.48M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $1.63M 10-Q · filed 2026-05-13 | $2.29M derived: sum of 2 quarters · filed 2026-05-13 | $4.89M derived: sum of 3 quarters · filed 2026-05-13 | $6.63M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $664.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $3.26M derived: sum of 2 quarters · filed 2026-03-12 | $5.00M derived: sum of 3 quarters · filed 2026-08-12 | $6.74M 10-K · filed 2026-03-12 |
| 2025-09-30 | $2.60M 10-Q · filed 2025-11-13 | $4.33M derived: sum of 2 quarters · filed 2026-08-12 | $6.08M 10-Q · filed 2025-11-13 | $7.83M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $1.74M 10-Q · filed 2026-08-12 | $3.48M 10-Q · filed 2026-08-12 | $5.23M derived: sum of 3 quarters · filed 2026-08-12 | $6.88M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $1.74M 10-Q · filed 2026-05-13 | $3.50M derived: sum of 2 quarters · filed 2026-05-13 | $5.14M derived: sum of 3 quarters · filed 2026-05-13 | $7.45M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $1.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $3.40M derived: sum of 2 quarters · filed 2026-03-12 | $5.71M derived: sum of 3 quarters · filed 2026-03-12 | $6.79M 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.65M 10-Q · filed 2025-11-13 | $3.95M derived: sum of 2 quarters · filed 2025-11-13 | $5.04M 10-Q · filed 2025-11-13 | $6.33M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $2.31M 10-Q · filed 2025-08-14 | $3.39M 10-Q · filed 2025-08-14 | $4.69M derived: sum of 3 quarters · filed 2025-08-14 | $6.13M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $1.08M 10-Q · filed 2025-05-15 | $2.38M derived: sum of 2 quarters · filed 2025-05-15 | $3.83M derived: sum of 3 quarters · filed 2025-05-15 | $5.45M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $2.74M derived: sum of 2 quarters · filed 2025-03-19 | $4.36M derived: sum of 3 quarters · filed 2025-03-19 | $5.75M 10-K · filed 2025-03-19 |
| 2023-09-30 | $1.44M 10-Q · filed 2024-11-05 | $3.06M derived: sum of 2 quarters · filed 2024-11-05 | $4.46M 10-Q · filed 2024-11-05 | $5.96M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $1.62M 10-Q · filed 2024-08-08 | $3.02M 10-Q · filed 2024-08-08 | $4.52M derived: sum of 3 quarters · filed 2024-08-08 | $6.32M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.40M 10-Q · filed 2024-05-09 | $2.90M derived: sum of 2 quarters · filed 2024-05-09 | $4.70M derived: sum of 3 quarters · filed 2024-05-09 | $5.60M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $3.30M derived: sum of 2 quarters · filed 2024-03-14 | $4.21M derived: sum of 3 quarters · filed 2024-03-14 | $4.80M 10-K · filed 2024-03-14 |
| 2022-09-30 | $1.79M 10-Q · filed 2023-11-09 | $2.70M derived: sum of 2 quarters · filed 2023-11-09 | $3.30M 10-Q · filed 2023-11-09 | $3.90M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $906.00K 10-Q · filed 2023-08-09 | $1.50M 10-Q · filed 2023-08-09 | $2.10M derived: sum of 3 quarters · filed 2023-08-09 | $2.70M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $597.00K 10-Q · filed 2023-05-11 | $1.19M derived: sum of 2 quarters · filed 2023-05-11 | $1.79M derived: sum of 3 quarters · filed 2023-05-11 | $2.31M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $597.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $1.19M derived: sum of 2 quarters · filed 2023-03-16 | $1.71M derived: sum of 3 quarters · filed 2023-03-16 | $2.26M 10-K · filed 2023-03-16 |
| 2021-09-30 | $597.00K 10-Q · filed 2022-11-10 | $1.11M derived: sum of 2 quarters · filed 2022-11-10 | $1.66M 10-Q · filed 2022-11-10 | $2.05M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $514.00K 10-Q · filed 2022-08-11 | $1.06M 10-Q · filed 2022-08-11 | $1.45M derived: sum of 3 quarters · filed 2022-08-11 | $1.75M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $548.00K 10-Q · filed 2022-05-16 | $936.00K derived: sum of 2 quarters · filed 2022-05-16 | $1.23M derived: sum of 3 quarters · filed 2022-05-16 | $1.36M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $388.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $683.00K derived: sum of 2 quarters · filed 2022-03-17 | $809.00K derived: sum of 3 quarters · filed 2022-03-17 | $935.00K 10-K · filed 2022-03-17 |
| 2020-09-30 | $295.00K 10-Q · filed 2021-11-10 | $421.00K derived: sum of 2 quarters · filed 2021-11-10 | $547.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $126.00K 10-Q · filed 2021-08-12 | $252.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |